Stock Analysis

Yushin Precision Equipment Second Quarter 2025 Earnings: EPS: JP¥12.64 (vs JP¥12.05 in 2Q 2024)

TSE:6482
Source: Shutterstock

Yushin Precision Equipment (TSE:6482) Second Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥6.54b (up 23% from 2Q 2024).
  • Net income: JP¥430.1m (up 4.9% from 2Q 2024).
  • Profit margin: 6.6% (down from 7.7% in 2Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥12.64 (up from JP¥12.05 in 2Q 2024).
earnings-and-revenue-history
TSE:6482 Earnings and Revenue History November 20th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yushin Precision Equipment's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Yushin Precision Equipment.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:6482

Yushin Precision Equipment

Engages in the development, production, sale, and maintenance of take-out robots for injection-molded products and peripheral equipment in Japan, North America, Asia, and Europe.

Flawless balance sheet with solid track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor